• Optimi Health Corp. Common Shares is trading 6% down at $4.85 in pre-market, appearing to be a result of profit-taking after a major news-driven rally.
  • On Monday, the stock surged after the company announced it had secured a supply of naturally derived ibogaine and would commence development of a finished drug product.
  • The "Ibogaine Initiative" news is significant as the compound is being investigated to treat PTSD and opioid use disorder, and was recently prioritized for accelerated FDA review by a U.S. executive order.
  • Today's pullback follows yesterday's strong gains as investors digest the strategic update.